2 news items
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
patients," said Carey Hwang, M.D., Ph.D., Vir's Senior Vice President, Clinical Research. "We are proud of the continued progress towards our goal
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VIR
22 Feb 24
that recognize HIV epitopes with the goal of creating a safe and effective HIV vaccine
- Prev
- 1
- Next